Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease [6]

Bone Marrow Transplantation

Volumn 40, Issue 3, 2007, Pages 295-296

  Prot Labarthe, S ^a   Therrien, R ^a   Champagne, M A ^a   Duval, M ^a   Joubert, C ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT VERSUS HOST DISEASE; CASE REPORT; COMBINED IMMUNODEFICIENCY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; GASTROINTESTINAL DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; LETTER; MALE; PRIORITY JOURNAL; SKIN DISEASE; SKIN EXFOLIATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG TOXICITY; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; SEVERE COMBINED IMMUNODEFICIENCY; SKIN DISEASES; TACROLIMUS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 34547235567     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705726     Document Type: Letter

References (8)

1. Hochleitner BW, Bosmuller C, Nehoda H, Fruhwirt M, Simma B, Ellemunter H et al. Increased tacrolimus levels during diarrhea. Transpl Int 2001; 14: 230-233.
2. Harper J, Smith C, Rubins A, Green A, Jackson K, Zigure S et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005; 124: 695-699.
3. Food and Drug Administration. Protopic® (tacrolimus) Ointment 0.03% Ointment 0.1% Monography. http://www.fda.gov/cder/foi/label/2006/ 050777s0121bl.pdf.
4. Simpson D, Noble S. Tacrolimus ointment: A review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 2005; 65: 827-858.
5. Allen A, Siegfried E, Silverman R, Williams ML, Elias PM, Szabo SK et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137: 747-750.
6. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Arch Dermatol 2002; 138: 1259-1260.
7. Russell RK, Richardson N, Wilson DC. Systemic absorption with complications during topical tacrolimus treatment for orofacial. Crohn disease. J Pediatr Gastroenterol Nutr 2001; 32: 207-208.
8. Shah KN, Yan AC. Low but detectable serum levels of tacrolimus seen with the use of very dilute, extemporaneously compounded formulations of tacrolimus ointment in the treatment of patients with Netherton syndrome. Arch Dermatol 2006; 142: 1362-1363.